UNSPSC 51313403: Betahistine

This classification denotes a vasodilating agent with the molecular formula C8H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X32KK4201D, chemically known as 2-pyridineethanamine, n-methyl- but generally known as betahistine, which bears US NIH Compound Identifier 2366. Betahistine most often comes in base, dihydrochloride, hydrochloride, and mesylate forms. European Medicines Agency schedules Betahistine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05794MIG.

UNSPSC 51313403 Betahistine is a Commodity code that describes a single pharmaceutical product — betahistine, a vestibular-function agent — but recent state and local procurement activity under this code does not align with the nominal scope. Instead, issuing bodies are tagging opportunities for broader pharmaceutical procurement, including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. The mismatch between the code's narrow pharmaceutical name and the expansive work actually being solicited suggests either miscoding by procurement offices or upstream taxonomy misalignment. State and local buyers pursuing these opportunities include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work itself ranges from direct purchase of specified pharmaceutical units with quarterly delivery requirements to market-intelligence gathering about alternative pharmacy distribution models and broad vendor qualification for generic pharmaceutical supply contracts.

The most recent activity appears concentrated in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission released Request for Information HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with a March 26, 2026 response deadline, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. No explicit set-aside designations appear in the available documentation, though all opportunities require E-Verify compliance and standard insurance coverage thresholds.